Product Information
FT SINUS SEVERE 325-200-5 MG is a generic product labeled by Strategic Sourcing Services LLC, priced at $0.1111 per EA under NDC 70677100501. Its NADAC has been published 161 times since Sep 6, 2023.
FT SINUS SEVERE 325-200-5 MG
ACETAMINOPHEN, GUAIFENESIN, and PHENYLEPHRINE HYDROCHLORIDEStrength
325; 200; 5 mg/1; mg/1; mg/1
Manufacturer
Strategic Sourcing Services LLCNDC
70677100501
Classification
Generic
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
4/25/2023
Pharmacological Classes
Price Statistics
The NADAC for FT SINUS SEVERE 325-200-5 MG has been published 161 times since Sep 6, 2023, and over the history we have for it it has risen 2.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1111 per EA |
|---|---|
| All-time high | $0.1200 (May 15, 2024) |
| All-time low | $0.1017 (Sep 20, 2023) |
| 52-week high | $0.1167 |
| 52-week low | $0.1047 |
| Median price | $0.1127 |
| Average price | $0.1118 |
| Largest weekly change | +11.9% (Apr 17, 2024) |
| Weeks tracked | 161 |
| Tracking since | Sep 6, 2023 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strategic Sourcing Services LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACETAMINOPHEN, GUAIFENESIN, and PHENYLEPHRINE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Expectorant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FT SINUS SEVERE 325-200-5 MG?
The current National Average Drug Acquisition Cost (NADAC) for FT SINUS SEVERE 325-200-5 MG, manufactured by Strategic Sourcing Services LLC, is $0.1111 per EA (NDC 70677100501), effective Sep 30, 2026.
How has the price of FT SINUS SEVERE 325-200-5 MG changed over time?
Over the history we have for it, the NADAC for FT SINUS SEVERE 325-200-5 MG has risen 2.7%. It has been tracked across 161 weekly CMS publications since Sep 6, 2023.
What are the highest and lowest recorded NADAC prices for FT SINUS SEVERE 325-200-5 MG?
Since Sep 6, 2023, the NADAC for FT SINUS SEVERE 325-200-5 MG has ranged from a low of $0.1017 (Sep 20, 2023) to a high of $0.1200 (May 15, 2024), with a median of $0.1127 per EA.
Are there cheaper alternatives to FT SINUS SEVERE 325-200-5 MG?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FT SINUS SEVERE 325-200-5 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures FT SINUS SEVERE 325-200-5 MG?
FT SINUS SEVERE 325-200-5 MG (NDC 70677100501) is labeled by Strategic Sourcing Services LLC, and CMS classifies it as a generic product.